Drug intelligence / Profile preview

MB14

Development stage: Preclinical
Lead developer: mAbxience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MB14 is a monoclonal antibody biosimilar currently in preclinical development by mAbxience in collaboration with Libbs. It is being developed for applications within the field of hematology. As of early 2025, the asset is positioned in Stage 0 (Clone and Proof of Concept) of the mAbxience pipeline. While the specific reference biologic and molecular target have not been publicly disclosed, MB14 represents an expansion of the developers' biosimilar portfolio, which already includes established products like rituximab (MB01) and bevacizumab (MB02). The development is part of a strategic partnership between the Spanish biotechnology company mAbxience and the Brazilian pharmaceutical firm Libbs.

Targets

PCNA (Proliferating cell nuclear antigen)

Beyond the preview

Go deeper on MB14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB14.

Explore the full profile